Objective To evaluate the clinical effect and safety of gemcitabine plus carboplatin regimen in the treatment of advanced non-small cell lung cancer(NSCLC) in aged patients. Methods 110 cases of aged patients with NSCLC , were divided into GEM group and NVB group according to the patients "options. GEM group received 1 000 mg/m2, GEM at day 1 and 8, and AUC 5 CBP at day 1. NVB group underwent the therapy of 2.5 mg/m2, NVB at day 1 and8,and 80 mg/m2 DDP at day 1 and 3. Both were treated with 21 days as a cycle. Results Overall re-sponse rate was 75.0% in GEM group and 72.0% in NVB group without significant difference( P>0.05). The medi-an survival time(MST) ,disease median response time(DPT) and one year survival rate were similar in two groups( P>0.05). The incidence of adverse reactions was significantly lower in GEM group than in NVB group ( P<0.05 ).Conclusion Gemcitabine plus carboplatin regimen is effective and safe in treatment of advanced non-small cell lung cancer in aged patients

Objective To evaluate the effect of LTA on lung function in stable chronic obstructive pulmonary disease. Methods A randomized and double blind placebo-controlled clinical trail was conducted in 84 patients with COPD. 42 patients were treated by LTA and 42 patients were treated by placebo for 12 weeks. Results LTA provided significant improvement in inspiratory capacity(IC) ,forced expiratory volume in one second(FEV) and forced vital capacity(FVC). Conclusion LTA is an effective bronchodilator on improving lung function and health status in patients with stable COPD.